Justin B. Klee, Co-Chief Executive Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 276,376 shares at $13.58 ($3.8M) on 2026-01-15, disclosed to the SEC on 2026-01-20.
Seasonal sale ($3.8M) by Co-Chief Executive Officer — this insider has traded AMLX in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.58 | 136,193 | $1.8M | 49.3% |
| 2 | $13.58 | 136,193 | $1.8M | 49.3% |
| 3 | $13.89 | 1,995 | $28K | 0.7% |
| 4 | $13.89 | 1,995 | $28K | 0.7% |
| Total | $13.59 avg | 276,376 | $3.8M | 100% |
| Filing → |
| AMLX | SELL | 2026-02-04 | $228K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $86K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $859K | — | Filing → |